Continued access to apixaban for children with heart disease
Treatments studied
This program lets children who were already taking apixaban in an earlier study continue getting the medicine. It is for kids with heart disease who need long-term protection from blood clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a heart condition (either from birth or developed later) and need long-term medicine to prevent blood clots.
- You must have taken part in an earlier apixaban study (called CV185-362) and been on apixaban for at least 1 year.
- Your weight must be between 5 and 35 kilograms (about 11 to 77 pounds).
- Your doctor must confirm that you still need this kind of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This trial tests whether the blood thinner apixaban can prevent dangerous blood clots from forming in the heart's main pumping chamber after a specific type of heart attack. It is for patients who have severe weakness of the left ventricle and no clot already present.
This trial tests how well patients with atrial fibrillation take their apixaban medication and whether it is safe. It aims to see if using apixaban for the first time works well without causing bleeding problems.
This study tests a blood thinner called rivaroxaban in children who have a blood clot inside the heart. The goal is to see if it safely and effectively dissolves the clot, potentially avoiding the need for stronger treatments.
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
This study compares a drug called apixaban (a blood thinner) with usual care to treat blood clots in the calf veins. The goal is to see if apixaban reduces the risk of the clot worsening or moving to a more dangerous location.